Glaukos Sole Source Implant Contract for UNM Hospital

This three‑year sole‑source agreement authorizes the University of New Mexico Hospital to purchase Glaukos glaucoma implants for use during cataract surgery, creating a permanent opening in the trabecular meshwork to better control intra‑ocular pressure. The contract is valued at $240,000 and is justified on the basis of unique expertise and exclusive FDA approval for the device. • Product: FDA‑approved Glaukos glaucoma implant (PMA #080030) used intra‑operatively with cataract procedures. • Term: 3‑year period (04/20/2026 – 04/20/2029) with a renewal option. • Value: $240,000 total (~$80,000 per year), firm‑fixed‑price. • Sole‑source justification: Only Glaukos holds the required regulatory clearance; no competitive alternatives exist.